Tindamax® Has the Right Combination for Comfortable BV Therapy

Switch to mobile view »

Excellent tolerability plus low incidence of GI side effects

Tindamax® is a second-generation nitroimidazole. While chemically related to metronidazole, it has a more favorable pharmacokinetic profile, longer plasma half-life, and significantly reduced incidence of side effects.

Pharmacokinetic profile: plasma half-life1

Chart illustrating the plasma half-life of tinidazole (12-14 hours) vs metronidazole (6-8 hours).

Figure 1

In bacterial vaginosis

In a large-scale study of tinidazole for treatment of bacterial vaginosis, both oral dosing options (2 g × 2 days and 1 g × 5 days) provided effective therapy with a low incidence of nausea and other GI side effects typically associated with metronidazole therapy.2

Tolerability comparison: Tindamax® vs placebo
Side effect profile Tinidazole 1 g qd for 5 days Tinidazole 2 g qd for 2 days Placebo Total
Number of participants 77 78 80 235
Any gastrointestinal symptom(s) 19 (24.7) 25 (32.1) 18 (22.5) 62 (26.0)
Dysgeusia (bad or metallic taste in mouth) 20 (26.0)* 31 (39.7)* 4 (5.0) 55 (23.4)
Headache 9 (11.7) 14 (17.9) 13 (16.3) 36 (15.3)
Nausea 8 (10.4) 14 (17.9)† 6 (7.5) 28 (11.9)
Abdominal discomfort 7 (9.1) 4 (5.1) 6 (7.5) 17 (7.2)
Vulvovaginal discomfort 7 (9.1) 7 (9.0) 2 (2.5) 16 (6.8)
Genital pruritus (female) 6 (7.8) 5 (6.4) 2 (2.5) 13 (5.5)
Fatigue 1 (1.3) 4 (5.1) 6 (7.5) 11 (4.7)
Dizziness 4 (5.2) 4 (5.1) 1 (1.3) 9 (3.8)
Vaginal discharge 2 (2.6) 3 (3.8) 3 (3.8) 8 (3.4)
Urine abnormality 3 (3.9) 4 (5.1) 1 (1.3) 8 (3.4)
Stomach discomfort 2 (2.6) 3 (3.8) 2 (2.5) 7 (3.0)
Vaginal candidiasis 4 (5.2) 2 (2.6) 1 (1.3) 7 (3.0)
Diarrhea 1 (1.3) 2 (2.6) 2 (2.5) 5 (2.1)
Vaginal odor 1 (1.3) 1 (1.3) 3 (3.8) 5 (2.1)

Adverse events reported in more than 2% of participants, tinidazole treatment of bacterial vaginosis, intent-to-treat population2

Data are n (%). A patient was counted, at most, once per preferred term, system organ class, or any event.

* P<0.001 compared with placebo.

P<0.5 compared with placebo.

Table 1

In trichomoniasis

Tinidazole also demonstrated excellent tolerability during a study evaluating 2-g × 1-day dosing for trichomoniasis3 and was found to be a "potent and well-tolerated option" vs metronidazole in another TV treatment study.4

Incidence of GI adverse events: Pooled data from 3 comparative studies3,5,6

Chart summarizing GI adverse events. Results represent pooled data from 3 studies comparing single-dose 2 g tinidazole vs 2 g metronidazole in patients with trichomoniasis. Nausea, vomiting, and diarrhea were common events reported in all 3 studies. Other events included anorexia, bitter taste, abdominal pain, giddiness, general weakness, constipation, pressure over stomach, pruritus, vertigo, and dark urine.

Figure 2

Simplify dosing and reduce complications

With the convenience of oral treatment, short dosing schedules, and reduced complications from secondary vaginal candidiasis, Tindamax® offers a simple, effective solution to treating bacterial vaginosis and trichomoniasis as well as GI infections.

  • Research shows that patients prefer oral therapy vs vaginal creams in the treatment of BV1
  • Compared to metronidazole, Tindamax® therapy requires fewer than half the doses required for effective BV treatment2
  • Tindamax® targets infection-causing pathogens while sparing protective lactobacilli; this results in a lower risk of secondary vaginal candidiasis, a treatment complication that can increase patient return rates
  1. Data on file. Mission Pharmacal Company.
  2. Livengood CH 3rd, Ferris DG, Wiesenfeld HC, Hillier SL, Soper DE, Nyirjesy P, Marrazzo J, Chatwani A, Fine P, Sobel J, Taylor SN, Wood L, Kanalas JJ. Effectiveness of two tinidazole regimens in treatment of bacterial vaginosis: a randomized controlled trial. Obstet Gynecol. 2007 Aug;110(2 Pt 1):302-9.
  3. Manorama HT, Shenoy DR. Single-dose oral treatment of vaginal trichomoniasis with tinidazole and metronidazole. J Int Med Res. 1978;6(1):46-9.
  4. Nanda N, Michel RG, Kurdgelashvili G, Wendel KA. Trichomoniasis and its treatment. Expert Rev Anti Infect Ther. 2006 Feb;4(1):125-35.
  5. Anjaeyulu R, Gupte SA, Desai DB. Single-dose treatment of trichomonal vaginitis: a comparison of tinidazole and metronidazole. J Int Med Res. 1977;5(6):438-41.
  6. Weidenbach A, Leix H. Treatment of trichomonal vaginitis with a single dose of tinidazole. Curr Med Res Opin. 1974;2(3):147-52.

Only Tindamax® is approved to treat both bacterial vaginosis and trichomoniasis (TV).

Clinical Insight

Oral vs vaginal cream therapy: Patient preference for oral dosing is demonstrated to be 84%. More»

Beyond BV

Tindamax® may be prescribed for other infections including: